RE: Have a look at this:

[Guest guest]

> http://www.leg.state.vt.us/docs/legdoc.cfm?

> URL=/docs/2006/resolutn/JRH006.HTM

Some folks may have trouble accessing the page. Here's the text as shown (Thank

you,

Rep. Obuchowski.):

--

House of Representatives

Montpelier, Vermont

Joint House Resolution

J.R.H. 6

Joint resolution urging the Food and Drug Administration and the Multiple

Sclerosis

Society to study the efficacy of low dose naltrexone as a multiple sclerosis

medication

Offered by: Representative Obuchowski of Rockingham

Whereas, multiple sclerosis (MS) is an inflammatory disease of the central

nervous

system (CNS) that damages the myelin sheath or insulating material that

surrounds the

nerve fibers in the brain, spinal cord, and optic nerves, and

Whereas, MS is characterized by attacks known as " flare-ups " or

exacerbations which

may be associated with plaques that prevent conduction of nerve impulses in the

CNS, and

Whereas, MS is most likely to occur in persons ages 20 to 40, and women are

two to

three times as likely as men to contract the disease, and

Whereas, no two cases of MS are identical, and although some persons go for

years

with no symptoms, lesions may still be forming in the CNS, and

Whereas, in the United States, it is estimated approximately 350,000

individuals live

with MS, and nearly 200 cases are diagnosed each week, and

Whereas, Vermont has the highest percentage of MS cases per capita of any

state in the

nation, and

Whereas, there is a variety of approved drugs for treating MS that have

varying degrees

of success, and

Whereas, one drug that is not currently approved for MS treatment, but in

private use

has reportedly been effective, is low dose naltrexone (LDN), and

Whereas, although neither the United States Food and Drug Administration

(FDA) nor

the National Multiple Sclerosis Society has conducted any official trials on the

effectiveness

of LDN, unofficial trials have shown a high degree of success in arresting the

disease's

progression, although problems have occurred in individuals who are exposed to

undue

fatigue, heat or a febrile illness, and

Whereas, despite this caveat, the overwhelmingly positive reports on the impact

of LDN for

MS patients merits official clinical trials under the auspices of the National

Multiple

Sclerosis Society, now therefore be it

Resolved by the Senate and House of Representatives:

That the General Assembly urges both the United States Food and Drug

Administration

and the Multiple Sclerosis Society to conduct scientifically valid clinical

trials to assess the

effectiveness and ramifications of low dose naltrexone as a medication for

treating

multiple sclerosis, and be it further

Resolved: That the United States Congress appropriate funds to support the

federal

research, and be it further

Resolved: That a copy of this resolution be sent to Acting FDA Commissioner Dr.

Lester

Crawford, to President and Chief Executive Officer of the National Multiple

Sclerosis

Society, Dugan, to the members of the Vermont Congressional Delegation,

and to

Seth and Candi Sawyer in Westminster.

____________________________ Attested to:

Gaye R. Symington

Speaker of the House

____________________________ ____________________________

E. Dubie G. Milne

President of the Senate Clerk, House of

Representatives

Published by:

The Vermont General Assembly

115 State Street

Montpelier, Vermont

www.leg.state.vt.us

[Guest guest]

This link was broken because it was truncated to the first line, but I urge anyone who is interested in reading this important news topic to try to read this link again: it's http://www.leg.state.vt.us/docs/legdoc.cfm?URL=/docs/2006/resolutn/JRH006.HTM. What this is is a resolution from the

State of Vermont

House of Representatives

Montpelier, Vermont

Joint House Resolution

J.R.H. 6

Joint resolution urging the Food and Drug Administration and the Multiple Sclerosis Society to study the efficacy of low dose naltrexone as a multiple sclerosis medication...

Rae

From: low dose naltrexone [mailto:low dose naltrexone ] On Behalf Of maxbtmSent: Monday, June 20, 2005 9:41 AMlow dose naltrexone Subject: [low dose naltrexone] Have a look at this:

http://www.leg.state.vt.us/docs/legdoc.cfm?URL=/docs/2006/resolutn/JRH006.HTM